Epigral Limited (Epigral), India’s leading integrated chemical manufacturer announced its financial results for the quarter ended September 30, 2024. The company posted a robust growth in PAT for Q2FY25 at Rs 81 Crore, a jump of 111% as compared to Rs 38 Crore in Q2FY24. The company’s quarterly revenue rose by 32% to Rs 632 Crore as against Rs 479 Crore recorded in Q2FY24.
Epigral’s board has approved the expansion project of CPVC and Epichlorohydrin (ECH). CPVC resin capacity will be expanded to 1,50,000 TPA (Tonnes Per Annum) by adding another 75,000 TPA capacity and Epichlorohydrin (ECH) capacity will be enhanced to 1,00,000 TPA by adding another 50,000 TPA capacity, at the company’s Dahej facility in Gujarat.
With this expansion, Epigral's total CPVC resin capacity will be elevated as the largest resin facility in the world and Epichlorohydrin will be the largest facility in India.
CPVC and ECH expansions will meet the growing demand of these products in India. The organization's move to further expand into CPVC resin and ECH production is consistent with the Government of India’s initiatives like Atmanirbhar Bharat and Make in India initiatives, which aim to make India more self-reliant.
With focus towards sustainability and environment, Epigral will be investing in Pure.rBrineTM technology for the recycling and reuse of by-product to use it as a raw material for other products. This will help in saving on waste discharge and reducing GHG emission from the overall supply chain. Further, the company will benefit from cost rationalization on account of strengthening integrated complex by consuming by-product as a raw material.
